Clinical Observation Of Shenmai Yifei Decoction In The Treatment Of Sjogren's Syndrome Secondary Interstitial Lung Disease With Yin Deficiency And Blood Stasis Syndrome

Objective:By observing the clinical efficacy and safety of Shenmai Yifei Decoction for patients with Sjogren's syndrome secondary to interstitial lung disease,so as to provide evidence-based medical evidence for the clinical application and further promotion of this Chinese medicine prescription.Methods:Forty patients meeting the inclusion criteria were divided into a control group and a treatment group of 20 patients each according to the principle of randomization;the control group was treated with conventional western medicine(methylprednisolone +cyclophosphamide),and the treatment group was supplemented with reference Mai Yifei Decoction is treated with Chinese medicine decoction,and the course of treatment is 12 weeks.Changes in clinical symptoms,TCM syndromes,laboratory indicators,lung function,and lung HRCT were compared before and after treatment.Results:1.The total effective rate in the control group was 70%,and the total effective rate in the treatment group was 95%.After testing,the difference between the two groups was statistically significant(P <0.05),indicating that both groups can improve clinical efficacy,and the treatment group is better than the Control group;2.In terms of improving TCM syndrome scores,both groups can effectively improve(P <0.01).Comparing the two groups after treatment,the difference between the control group and the treatment group is statistically significant(P <0.01),indicating that the improvement of TCM syndrome scores in the treatment group is better than that in the control group;3.In terms of laboratory indicators,no significant difference was seen between the positive rates of anti-SSA antibodies and anti-SSB antibodies before and after treatment between the two groups(P> 0.05),indicating that the anti-SSA antibodies and anti-SSB antibodies of the treatment group and the control group were both No significant effect.By comparing the CRP and ESR before and after treatment,the differences between the control group and the treatment group are statistically significant(P <0.01),indicating that both groups can reduce CRP and ESR levels,and the CRP reduction effect of the treatment group is better than the control group(P< 0.05);4.In terms of lung function,including vital capacity(VC),total lung capacity(TLC),and carbon monoxide dispersion(DLco),the two groups increased to varying degrees after treatment,and the differences were statistically significant after testing(P < 0.01),indicating that both groups are effective in improving lung function after treatment.After comparison between the two groups after treatment,there was no significant difference between the treatment group and the control group(P> 0.05);5.According to the comparison of lung HRCT scores before and after treatment,it is considered that the treatment group has a certain improvement in lung HRCT(P<0.05),but the control group has no significant improvement(P> 0.05).6.No significant adverse event was added during the treatment,which indicates that the clinical safety of Shenmai Yifei Decoction is acceptable and worthy of clinical application.Conclusion:Shenmai Yifei Decoction has good curative effect on yin deficiency and stasis syndrome secondary to Sjogren's syndrome with interstitial lung disease.It is safe and reliable.It can significantly improve clinical symptoms,reduce laboratory indicators,improve lung function,control the disease,and delay the course of the disease.